SEARCH

SEARCH BY CITATION

References

  • 1
    Iacobelli S, Arno E, Sismondi P, Natoli C, Gentiloni N, Scambia G, Giai M, Cortese P, Panici PB, Mancuso S. Measurement of a breast cancer associated antigen detected by monoclonal antibody SP-2 in sera of cancer patients. Breast Cancer Res Treat 1988; 11: 1930.
  • 2
    Ullrich A, Sures I, D'Egidio M, Jallal B, Powell TJ, Herbst R, Dreps A, Azam M, Rubinstein M, Natoli C, Shawver LK, Schlessinger J, et al. The secreted tumor-associated antigen 90K is a potent immune stimulator. J Biol Chem 1994; 269: 184017.
  • 3
    Iacobelli S, Sismondi P, Giai M, D'Egidio M, Tinari N, Amatetti C, Di Stefano P, Natoli C. Prognostic value of a novel circulating serum 90K antigen in breast cancer. Br J Cancer 1994; 69: 1726.
  • 4
    Ozaki Y, Kontani K, Hanaoka J, Chano T, Teramoto K, Tezuka N, Sawai S, Fujino S, Yoshiki T, Okabe H, Ohkubo I. Expression and immunogenicity of a tumor-associated antigen, 90K/Mac-2 binding protein, in lung carcinoma. Cancer 2002; 95: 195462.
  • 5
    Marchetti A, Tinari N, Buttitta F, Chella A, Angeletti CA, Sacco R, Mucilli F, Ullrich A, Iacobelli S. Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. Cancer Res 2002; 62: 25359.
  • 6
    Scambia G, Panici PB, Baiocchi G, Perrone L, Iacobelli S, Mancuso S. Measurement of a monoclonal-antibody-defined antigen (90K) in the sera of patients with ovarian cancer. Anticancer Res 1988; 8: 7614.
  • 7
    Kunzli BM, Berberat PO, Zhu ZW, Martignoni M, Kleeff J, Tempia-Caliera AA, Fukuda M, Zimmermann A, Friess H, Buchler MW. Influences of the lysosomal associated membrane proteins (Lamp-1, Lamp-2) and Mac-2 binding protein (Mac-2-BP) on the prognosis of pancreatic carcinoma. Cancer 2002; 94: 22839.
  • 8
    Fornarini B, D'Ambrosio C, Natoli C, Tinari N, Silingardi V, Iacobelli S. Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. Blood 2000; 96: 32825.
  • 9
    Natoli C, Iacobelli S, Ghinelli F. Unusually high level of a tumor-associated antigen in the serum of human immunodeficiency virus-seropositive individuals. J Infect Dis 1991; 164: 61617.
  • 10
    Artini M, Natoli C, Tinari N, Costanzo A, Marinelli R, Balsano C, Porcari P, Angelucci D, D'Egidio M, Levrero M, Iacobelli S. Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to α-interferon therapy in chronic HCV hepatitis patients. J Hepatol 1996; 25: 21217.
  • 11
    Grassadonia A, Tinari N, Iurisci I, Piccolo E, Cumashi A, Innominato P, D'Egidio M, Natoli C, Piantelli M, Iacobelli S. 90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj J 2004; 19: 5516.
  • 12
    Inohara H, Akahani S, Koths K, Raz A. Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res 1996; 56: 45304.
  • 13
    Muller SA, Sasaki T, Bork P, Wolpensinger B, Schulthess T, Timpl R, Engel A, Engel J. Domain organization of Mac-2 binding protein and its oligomerization to linear and ring-like structures. J Mol Biol 1999; 291: 80113.
  • 14
    Fusco O, Querzoli P, Nenci I, Natoli C, Brakebush C, Ullrich A, Iacobelli S. 90K (MAC-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells. Int J Cancer 1998; 79: 236.
  • 15
    Kalayci O, Birben E, Tinari N, Oguma T, Iacobelli S, Lilly CM. Role of 90K protein in asthma and TH2-type cytokine expression. Ann Allergy Asthma Immunol 2004; 93: 48592.
  • 16
    Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 201115.
  • 17
    Yasui W, Tahara E, Tahara H, Fujimoto J, Naka K, Nakayama J, Ishikawa F, Ide T. Immunohistochemical detection of human telomerase reverse transcriptase in normal mucosa and precancerous lesions of the stomach. Jpn J Cancer Res 1999; 90: 58995.
  • 18
    Yasui W, Oue N, Kuniyasu H, Ito R, Tahara E, Yokozaki H. Molecular diagnosis of gastric cancer: present and future. Gastric Cancer 2001; 4: 11321.
  • 19
    Yamada M, Tsuji N, Nakamura M, Moriai R, Kobayashi D, Yagihashi A, Watanabe N. Down-regulation of TRF1, TRF2 and TIN2 genes is important to maintain telomeric DNA for gastric cancers. Anticancer Res 2002; 22: 33037.
  • 20
    Yi X, Shay JW, Wright WE. Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells. Nucleic Acids Res 2001; 29: 481825.
  • 21
    Park JG, Yang HK, Kim WH, Chung JK, Kang MS, Lee JH, Oh JH, Park HS, Yeo KS, Kang SH, Song SY, Kang YK, et al. Establishment and characterization of human gastric carcinoma cell lines. Int J Cancer 1997; 70: 4439.
  • 22
    Park JG, Frucht H, LaRocca RV, Bliss DP,Jr, Kurita Y, Chen TR, Henslee JG, Trepel JB, Jensen RT, Johnson BE. Characteristics of cell lines established from human gastric carcinoma. Cancer Res 1990; 50: 277380.
  • 23
    Jong HS, Park YI, Kim S, Sohn JH, Kang SH, Song SH, Bang YJ, Kim NK. Up-regulation of human telomerase catalytic subunit during gastric carcinogenesis. Cancer 1999; 86: 55965.
  • 24
    Liu C, Sun C, Huang H, Janda K, Edgington T. Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res 2003; 63: 295764.
  • 25
    Kyo S, Kanaya T, Takakura M, Tanaka M, Inoue M. Human telomerase reverse transcriptase as a critical determinant of telomerase activity in normal and malignant endometrial tissues. Int J Cancer 1999; 80: 603.
  • 26
    Ulaner GA, Hu JF, Vu TH, Giudice LC, Hoffman AR. Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res 1998; 58: 416872.
  • 27
    Ulaner GA, Hu JF, Vu TH, Oruganti H, Giudice LC, Hoffman AR. Regulation of telomerase by alternate splicing of human telomerase reverse transcriptase (hTERT) in normal and neoplastic ovary, endometrium and myometrium. Int J Cancer 2000; 85: 3305.
  • 28
    Stoicov C, Saffari R, Cai X, Hasyagar C, Houghton J. Molecular biology of gastric cancer: Helicobacter infection and gastric adenocarcinoma: bacterial and host factors responsible for altered growth signaling. Gene 2004; 341: 117.
  • 29
    Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2: 528.
  • 30
    Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 32832.
  • 31
    Lee DH, Yang Y, Lee SJ, Kim KY, Koo TH, Shin SM, Song KS, Lee YH, Kim YJ, Lee JJ, Choi I, Lee JH. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res 2003; 63: 464855.
  • 32
    Yoon KA, Ku JL, Yang JO, Park JG. Telomerase activity, expression of Bcl-2 and cell cycle regulation in doxorubicin resistant gastric carcinoma cell lines. Int J Mol Med 2003; 11: 3438.
  • 33
    Iacobelli S, Arno E, D'Orazio A, Coletti G. Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res 1986; 46: 300510.
  • 34
    Resnick D, Pearson A, Krieger M. The SRCR superfamily: a family reminiscent of the Ig superfamily. Trends Biochem Sci 1994; 19: 58.
  • 35
    Ochwat D, Hoja-Lukowicz D, Litynska A. N-Glycoproteins bearing β-6 branched oligosaccharides from the A375 human melanoma cell line analysed by tandem mass spectrometry. Melanoma Res 2004; 14: 47985.
  • 36
    Powell TJ, Schreck R, McCall M, Hui T, Rice A, App H, Azam M, Ullrich A, Shawver LK. A tumor-derived protein which provides T-cell costimulation through accessory cell activation. J Immunother Emphasis Tumor Immunol 1995; 17: 20921.
  • 37
    Natoli C, Iacobelli S, Kohn L. The immune stimulatory protein 90K increases major histocompatibility complex class I expression in a human breast cancer cell line. Biochem Biophys Res Commun 1996; 225: 61720.
  • 38
    Kang HJ, Choi YS, Hong SB, Kim KW, Woo RS, Won SJ, Kim EJ, Jeon HK, Jo SY, Kim TK, Bachoo R, Reynolds IJ, et al. Ectopic expression of the catalytic subunit of telomerase protects against brain injury resulting from ischemia and NMDA-induced neurotoxicity. J Neurosci 2004; 24: 12807.
  • 39
    Klapper W, Shin T, Mattson MP. Differential regulation of telomerase activity and TERT expression during brain development in mice. J Neurosci Res 2001; 64: 25260.
  • 40
    Ulaner GA, Hu JF, Vu TH, Giudice LC, Hoffman AR. Tissue-specific alternate splicing of human telomerase reverse transcriptase (hTERT) influences telomere lengths during human development. Int J Cancer 2001; 91: 6449.
  • 41
    Hara T, Noma T, Yamashiro Y, Naito K, Nakazawa A. Quantitative analysis of telomerase activity and telomerase reverse transcriptase expression in renal cell carcinoma. Urol Res 2001; 29: 16.
  • 42
    Villa R, Porta CD, Folini M, Daidone MG, Zaffaroni N. Possible regulation of telomerase activity by transcription and alternative splicing of telomerase reverse transcriptase in human melanoma. J Invest Dermatol 2001; 116: 86773.
  • 43
    Yi X, White DM, Aisner DL, Baur JA, Wright WE, Shay JW. An alternate splicing variant of the human telomerase catalytic subunit inhibits telomerase activity. Neoplasia 2000; 2: 43340.
  • 44
    Colgin LM, Wilkinson C, Englezou A, Kilian A, Robinson MO, Reddel RR. The hTERT α splice variant is a dominant negative inhibitor of telomerase activity. Neoplasia 2000; 2: 42632.